Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins
Source: SeekingAlpha
2026-03-30 14:54:55 ET
More on Merck
- Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff
- Merck's Deal For Terns And Its Stellar CML Drug Candidate Looks Like Good Business
- Merck & Co., Inc. (MRK) M&A Call Transcript
- Former CDC advisor says White House pulling back on vaccine policy
- Anti-vaccine group asks RFK Jr. to add more vaccine injuries to compensation program
Read the full article on Seeking Alpha
For further details see:
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-2.44% G/L:
$746.865 Last:
236,740 Volume:
$771.48 Open:
REGN Latest News
April 02, 2026 04:30:00 pm
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
April 02, 2026 04:30:00 pm
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
